文献速递流行病学与生物统计基础与转化研究

测量误差下分层生物标志物试验的设计与分析

On the design and the analysis of stratified biomarker trials in the presence of measurement error.
PubMed 文献 · Stat Med · 2021-03-16

本文针对分层生物标志物设计,探讨生物标志物测量误差对检验治疗-生物标志物交互作用的影响。作者证明朴素检验存在偏倚,提出偏倚校正的样本量与95%置信区间估计方法,并给出调整错分率的样本量公式,应用于一项肾癌III期临床试验设计。

要点

  • 生物标志物测量误差会使分层生物标志物试验的交互作用检验产生偏倚并降低把握度。
  • 建议采用偏倚校正估计量计算样本量和95%置信区间。
  • 所提样本量公式可调整错分率,适用于生存结局的III期试验设计。

核心结论

  • 在分层生物标志物设计中,朴素交互作用检验存在偏倚,需采用偏倚校正方法计算样本量和95%置信区间。

研究设计与样本

  • 方法学论文,提出分层生物标志物试验的设计与分析框架,并给出调整错分率的样本量公式。
  • 将所提样本量公式应用于一项肾癌III期临床试验的设计。

主要发现

  • 生物标志物水平可能存在测量误差,对分层生物标志物临床试验的把握度产生不利影响。
  • 朴素检验存在偏倚,作者提供了偏倚校正估计量用于计算样本量和95%置信区间。

临床怎么用

  • 在分层生物标志物试验设计阶段应考虑生物标志物测量误差,使用偏倚校正方法估算样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A major emphasis in precision medicine is to optimally treat subgroups of patients who may benefit from certain therapeutic agents. And as such, enormous resources and innovative clinical trials designs in oncology are devoted to identifying predictive biomarkers. Predictive biomarkers are ones that will identify patients that are more likely to respond to specific therapies and they are usually discovered through retrospective analysis from large randomized phase II or phase III trials. One important design to consider is the stratified biomarker design, where patients will have their specimens obtained at baseline and the biomarker status will be assessed prior to random assignment. Regardless of their biomarker status, patients will be randomized to either an experimental arm or the standard of care arm. The stratified biomarker design can be used to test for a treatment-biomarker interaction in predicting a time-to event outcome. Many biomarkers, however, are derived from tissues from patients, and their levels may be heterogeneous. As a result, biomarker levels may be measured with error and this would have an adverse impact on the power of a stratified biomarker clinical trial. We present a trial design and an analysis framework for the stratified biomarker design. We show that the naïve test is biased and provide bias-corrected estimators for computing the sample size and the 95% confidence interval when testing for a treatment-biomarker interaction in predicting a time to event outcome. We propose a sample size formula that adjusts for misclassification and apply it in the design of a phase III clinical trial in renal cancer.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Halabi S, Lin CY, Liu A, et al. On the design and the analysis of stratified biomarker trials in the presence of measurement error. Stat Med. 2021. PMID: 33724513. doi:10.1002/sim.8928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。